Elevance Health stock faces 516 million US dollar CMS fight

Elevance Health filed a federal lawsuit on November 6 challenging the way CMS calculated its 2027 Medicare Advantage star ratings. Insurance Business reported that the insurer alleges CMS used 11 measures that were not adopted through the required formal rulemaking process.

Payment impact depends on court outcome

The complaint covers 12 Elevance contracts, including plans serving members in several US states, Puerto Rico and a national group. Elevance alleges that removing the disputed measures would lift each contract's rating by at least half a star.

The insurer estimates that corrected ratings could generate 516 million US dollars in additional 2028 quality bonus payments and rebate retention. The potential benefit depends on a court order, a CMS recalculation and the resulting contract ratings; no court has ruled on the merits.

Ratings remain tied to plan economics

Medicare Advantage star ratings influence bonus payments, rebate retention and how plans are presented to members and brokers. A rating move across the four-star threshold can therefore affect both funding and the competitive position of a contract.

The lawsuit adds a legal variable to Elevance's operating agenda. Investors are also watching Medicaid margin recovery, medical-cost control and whether the company can sustain its higher earnings baseline into 2027.

Elevance Health stock traded at 388.50 euros on Lang & Schwarz at 16:11 CET on Thursday, November 12, 2026.

The broader US equity market can be followed in the S&P 500 market overview.

Further developments are collected on the More news and analyses on Elevance Health stock page.